Role of Endogenous Opioid Peptides in HIV-associated Chronic Widespread Pain
Florida International University
Summary
To determine if decreased production or release of endogenous opioid peptides by peripheral immune cells contributes to hypersensitivity in people with HIV
Description
The prevalence of chronic widespread pain (CWP) in individuals infected with the human immunodeficiency virus (HIV-1) includes regional and widespread musculoskeletal pain of neuropathic and inflammatory nature. HIV-related CWP leads to 10x greater odds of functional impairment. However, the specific mechanisms that contribute to CWP in HIV are not understood. Thus, pharmacological and non-pharmacological approaches to mitigate CWP have had minimal benefits, contributing to an overreliance on opioids and alarming rise in addiction and overdose. The overall objective of this study is to address…
Eligibility
- Age range
- 19–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Confirmed HIV diagnosis and currently a patient in the UAB 1917 HIV Clinic * Age 19 - 65; the lower end of this age range was chosen to capture young adults with HIV infection, and participants over 65 years are increasingly likely to meet one or more exclusion criteria * All people living with HIV must be currently receiving stable antiretroviral therapy (ART) for inclusion in this study * Non-HIV participants must be confirmed as HIV negative. HIV-negative participants with chronic widespread pain must self-report bodily pain more than once per week for at least three…
Interventions
- DrugRelistor Injectable Product
Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
Location
- Ambulatory Care Center, Florida International UniversityMiami, Florida